Publications by authors named "Qiongzhen Yuan"
Retinal degenerative diseases were a large group of diseases characterized by the primary death of retinal ganglion cells (RGCs). Recent studies had shown an interaction between autophagy and nucleotide-binding oligomerization domain-like receptor 3 (NLRP3) inflammasomes, which may affect RGCs in retinal degenerative diseases. The NLRP3 inflammasome was a protein complex that, upon activation, produces caspase-1, mediating the apoptosis of retinal cells and promoting the occurrence and development of retinal degenerative diseases.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the impact of the NLRP3/autophagy pathway on inflammation in photoreceptors, focusing on the protective effects of CY-09 and astaxanthin (AST).
- ICR mice were divided into five groups and treated with different combinations of NaIO, CY-09, and AST; various assays were used to measure cell viability, apoptosis, and levels of inflammation-related proteins.
- Results indicate that both CY-09 and AST reduce inflammation and cell death in photoreceptors while inhibiting the NLRP3/autophagy pathway, suggesting they could offer protection against retinal inflammatory damage.
Article Synopsis
- Ultra-widefield fundus (UWF) imaging offers a 200° view of the retina, helping detect peripheral lesions better than traditional methods, but lacks strong diagnostic capabilities.
- This study developed an automated model using YOLOX to identify and locate six common peripheral retinal lesions from UWF images, facilitating early screening and rapid diagnosis.
- The model achieved high accuracy rates (up to 96.64%) and maintained excellent sensitivity and specificity across multiple datasets, indicating its effectiveness in diagnosing retinal lesions.
To compare the efficacy and safety of the intravitreal dexamethasone (DEX) implant for the treatment of diabetic macular edema (DME) in vitrectomized and nonvitrectomized eyes. We performed a literature search in four electronic databases (PubMed, EMBASE, MEDLINE, and Cochrane Library) from inception to 22 May 2022. Studies comparing the efficacy of the DEX implant in vitrectomized and nonvitrectomized eyes with DME with at least 3 months of follow-up were included.
View Article and Find Full Text PDFTo assess the functional and anatomical consequences of single-dose dexamethasone (DEX) implants for the treatment of refractory macular edema (ME) secondary to retinal vein occlusion (RVO) after anti-vascular endothelial growth factor agents. A literature search of studies on switching therapy to DEX implants from anti-VEGF agents in refractory RVO patients was performed with five electronic databases (PubMed, Embase, Web of Science, MEDLINE, and Cochrane Library) prior to January 2022. The main outcomes included best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes at different follow-up endpoints from baseline.
View Article and Find Full Text PDFEfficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis.
Graefes Arch Clin Exp Ophthalmol
February 2022
Purpose: This meta-analysis was conducted to evaluate the efficacy and safety of single-dose dexamethasone implantation for treating persistent DME (diabetic macular edema) refractory to anti-VEGF (anti-vascular endothelial growth factor) drugs over a period of 6 months.
Methods: All related clinical trials were reviewed by searching electronic databases of PubMed, Medline, Web of Science, Cochrane Library, and EMBASE. The primary outcome parameters were best-corrected visual acuity (BCVA) and central macular thickness (CMT).